Being the first to market and having commercial success do not prove novelty, the U.S. Court of Appeals for the Federal Circuit ruled Wednesday in affirming that the Patent Trial and Appeal Board (PTAB) rightly invalidated one of four patents protecting Novartis AG's blockbuster oral multiple sclerosis (MS) drug Gilenya from generic competition.